Skip to search formSkip to main contentSkip to account menu

Resectable Small Intestinal Carcinoma

Known as: Resectable Small Bowel Carcinoma, Small Intestine Carcinoma, Resectable, Resectable Carcinoma of the Small Intestine 
Carcinoma of the small intestine amendable to resection.
National Institutes of Health

Related topics

Related topics

12 relations
Abdominal PainCrohn DiseaseEpithelial CellsEpithelium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
Review
2016
Review
2016
Peri-operative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PDAC): A pilot study.
312 Background: Surgical resection plus adjuvant gemcitabine or 5-FU is standard therapy for resectable PDAC. Infusional 5-FU… 
2015
2015
Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC.
Review
2014
Review
2014
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
2014
2014
Influence of Pathologic Complete Response to Induction Chemotherapy onLong-Term Survival of Patients Advanced Squamous Cell Carcinoma of the OralCavity Tongue
Objective: To discuss long-term efficacy of preoperative induction chemotherapy (IC) plus surgery ± radiotherapy in patients with… 
2012
2012
Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.
2009
2009
Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial.
e15550 Background: Locally advanced esophageal cancer (LAEC) has a 5-year survival of < 30 %. Most patients (pts) fail after… 
2008
2008
Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac…
6037 Background: Epidermal growth factor receptor (EGFR) and G-protein-coupled receptor (GPCR) ligands, such as prostaglandin E2… 
2008
2008
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver
2007
2007
[Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially resectable non-small cell lung cancer].
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)